Oxidative stress in sickle cell disease; pathophysiology and potential implications for disease management

American Journal of Hematology

Volumn 86, Issue 6, 2011, Pages 484-489

  Nur, Erfan ^a,b   Biemond, Bart J ^b   Otten, Hans Martin ^a   Brandjes, Dees P ^a   Schnog, John John B ^a,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c Sint Elisabeth Hospital   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

REACTIVE OXYGEN METABOLITE;

ENDOTHELIAL DYSFUNCTION; HEMOLYSIS; HEMOLYTIC ANEMIA; HYPERCOAGULABILITY; INFECTION SENSITIVITY; INFLAMMATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SICKLE CELL ANEMIA;

ANEMIA, SICKLE CELL; DISEASE MANAGEMENT; HUMANS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 79956089142     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.22012     Document Type: Review

References (113)

1. Serjeant GR. The emerging understanding of sickle cell disease. Br J Haematol 2001; 112: 3-18.
2. Schnog JJ, Lard LR, Rojer RA, et al. New concepts in assessing sickle cell disease severity. Am J Hematol 1998; 58: 61-66.
3. Onwubalili JK. Sickle cell disease and infection. J Infect 1983; 7: 2-20.
4. Frenette PS. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol 2002; 9: 101-106.
5. van Beers EJ, van Tuijn CF, Mac Gillavry MR, et al. Sickle cell disease-related organ damage occurs irrespective of pain rate: Implications for clinical practice. Haematologica 2008; 93: 757-760.
6. Hebbel RP. The systems biology-based argument for taking a bold step in chemoprophylaxis of sickle vasculopathy. Am J Hematol 2009; 84: 543-545.
7. Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA 2001; 98: 15215-15220.
8. Nur E, Brandjes DP, Schnog JJ, et al. Plasma levels of advanced glycation end products are associated with haemolysis-related organ complications in sickle cell patients. Br J Haematol 2010; 151: 62-69.
9. Klings ES, Farber HW. Role of free radicals in the pathogenesis of acute chest syndrome in sickle cell disease. Respir Res 2001; 2: 280-285.
10. Nath KA, Grande JP, Croatt AJ, et al. Transgenic sickle mice are markedly sensitive to renal ischemia-reperfusion injury. Am J Pathol 2005; 166: 963-972.
11. Morris CR, Suh JH, Hagar W et al. Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease. Blood 2008; 111: 402-410.
12. Hebbel RP, Morgan WT, Eaton JW, et al. Accelerated autoxidation and heme loss due to instability of sickle hemoglobin. Proc Natl Acad Sci U S A 1988; 85: 237-241.
13. Nagababu E, Fabry ME, Nagel RL, et al. Heme degradation and oxidative stress in murine models for hemoglobinopathies: Thalassemia, sickle cell disease and hemoglobin C disease. Blood Cells Mol Dis 2008; 41: 61-66.
14. Akohoue SA, Shankar S, Milne GL et al. Energy expenditure, inflammation, and oxidative stress in steady-state adolescents with sickle cell anemia. Pediatr Res 2007; 61: 233-238.
15. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82: 47-95.
16. Tu BP, Weissman JS. Oxidative protein folding in eukaryotes: mechanisms and consequences. J Cell Biol 2004; 164: 341-346.
17. Halliwell B, Gutteridge JM. Lipid peroxidation, oxygen radicals, cell damage, and antioxidant therapy. Lancet 1984; 1: 1396-1397.
18. Jeney V, Balla J, Yachie A, et al. Pro-oxidant and cytotoxic effects of circulating heme. Blood 2002; 100: 879-887.
19. Kato GJ, Hebbel RP, Steinberg MH, et al. Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directions. Am J Hematol 2009; 84: 618-625.
20. Sheng K, Shariff M, Hebbel RP. Comparative oxidation of hemoglobins A and S. Blood 1998; 91: 3467-3470.
21. McCord JM. Iron, free radicals, and oxidative injury. J Nutr 2004; 134: 3171-3172.
22. Papanikolaou G, Pantopoulos K. Iron metabolism and toxicity. Toxicol Appl Pharmacol 2005; 202: 199-211.
23. Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8: 1383-1389.
24. Belhassen L, Pelle G, Sediame S, et al. Endothelial dysfunction in patients with sickle cell disease is related to selective impairment of shear stress-mediated vasodilation. Blood 2001; 97: 1584-1589.
25. Spiecker M, Darius H, Kaboth K, et al. Differential regulation of endothelial cell adhesion molecule expression by nitric oxide donors and antioxidants. J Leukoc Biol 1998; 63: 732-739.
26. Villagra J, Shiva S, Hunter LA, et al. Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood 2007; 110: 2166-2172.
27. Guzik TJ, Korbut R, Mek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 2003; 54: 469-487.
28. Balla J, Jacob HS, Balla G, et al. Endothelial-cell heme uptake from heme proteins: induction of sensitization and desensitization to oxidant damage. Proc Natl Acad Sci USA 1993; 90: 9285-9289.
29. Schnog JB, Rojer RA, Mac Gillavry MR, et al. Steady-state sVCAM-1 serum levels in adults with sickle cell disease. Ann Hematol 2003; 82: 109-113.
30. Kato GJ, Martyr S, Blackwelder WC, et al. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br J Haematol 2005; 130: 943-953.
31. Kato GJ. Haptoglobin halts hemoglobin's havoc. J Clin Invest 2009; 119: 2140-2142.
32. Boretti FS, Buehler PW, D'Agnillo F, et al. Sequestration of extracellular hemoglobin within a haptoglobin complex decreases its hypertensive and oxidative effects in dogs and guinea pigs. J Clin Invest 2009; 119: 2271-2280.
33. Balla J, Vercellotti GM, Jeney V, et al. Heme, Heme Oxygenase, and Ferritin: How the Vascular Endothelium Survives (and Dies) in an Iron-Rich Environment. Antioxid Redox Signal 2007; 9: 2119-2137.
34. Beetsch JW, Park TS, Dugan LL, et al. Xanthine oxidase-derived superoxide causes reoxygenation injury of ischemic cerebral endothelial cells. Brain Res 1998; 786: 89-95.
35. Nishino T, Nakanishi S, Okamoto K, et al. Conversion of xanthine dehydrogenase into oxidase and its role in reperfusion injury. Biochem Soc Trans 1997; 25: 783-786.
36. Kirschner RE, Fantini GA. Role of iron and oxygen-derived free radicals in ischemia-reperfusion injury. J Am Coll Surg 1994; 179: 103-117.
37. Ramos CL, Pou S, Britigan BE, et al. Spin trapping evidence for myeloperoxidase-dependent hydroxyl radical formation by human neutrophils and monocytes. J Biol Chem 1992; 267: 8307-8312.
38. Kiefmann R, Rifkind JM, Nagababu E, et al. Red blood cells induce hypoxic lung inflammation. Blood 2008; 111: 5205-5214.
39. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest 2000; 106: 411-420.
40. Dahlgren C, Karlsson A. Respiratory burst in human neutrophils. J Immunol Methods 1999; 232: 3-14.
41. Lard LR, Mul FP, de Haas M, et al. Neutrophil activation in sickle cell disease. J Leukoc Biol 1999; 66: 411-415.
42. Wun T. The Role of Inflammation and Leukocytes in the pathogenesis of sickle cell disease; haemoglobinopathy. Hematology 2001; 5: 403-412.
43. Wagener, Feldman E, de Witte T, et al. Heme induces the expression of adhesion molecules ICAM-1, VCAM-1, and E selectin in vascular endothelial cells. Proc Soc Exp Biol Med 1997; 216: 456-463.
44. Coletta M, Hofrichter J, Ferrone FA, et al. Kinetics of sickle haemoglobin polymerization in single red cells. Nature 1982; 300: 194-197.
45. Krajewski ML, Hsu LL, Gladwin MT. The proverbial chicken or the egg? Dissection of the role of cell-free hemoglobin versus reactive oxygen species in sickle cell pathophysiology. Am J Physiol Heart Circ Physiol 2008; 295: 4-7.
46. Hebbel RP, Osarogiagbon R, Kaul D. The endothelial biology of sickle cell disease: Inflammation and a chronic vasculopathy. Microcirculation 2004; 11: 129-151.
47. Sydow K, Munzel T. ADMA and oxidative stress. Atheroscler Suppl 2003; 4: 41-51.
48. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly. Am J Physiol 1996; 271: 1424-1437.
49. Singer ST, Ataga KI. Hypercoagulability in sickle cell disease and beta-thalassemia. Curr Mol Med 2008; 8: 639-645.
50. Hamer I, Wattiaux R, Wattiaux-De CS. Deleterious effects of xanthine oxidase on rat liver endothelial cells after ischemia/reperfusion. Biochim Biophys Acta 1995; 1269: 145-152.
51. Solovey A, Gui L, Key NS, et al. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest 1998; 101: 1899-1904.
52. Belcher JD, Mahaseth H, Welch TE, et al. Critical role of endothelial cell activation in hypoxia-induced vasoocclusion in transgenic sickle mice. Am J Physiol Heart Circ Physiol 2005; 288: H2715-H2725.
53. Ahmed N. Advanced glycation endproducts--role in pathology of diabetic complications. Diabetes Res Clin Pract 2005; 67: 3-21.
54. Somjee SS, Warrier RP, Thomson JL, et al. Advanced glycation end-products in sickle cell anaemia. Br J Haematol 2005; 128: 112-118.
55. Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Pathol 1993; 143: 1699-1712.
56. Goldin A, Beckman JA, Schmidt AM, et al. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 2006; 114: 597-605.
57. Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens 2003; 21: 3-12.
58. Landburg PP, Teerlink T, van Beers EJ, et al. Association of asymmetric dimethylarginine with sickle cell disease-related pulmonary hypertension. Haematologica 2008; 93: 1410-1412.
59. Kato GJ, Wang Z, Machado RF, et al. Endogenous nitric oxide synthase inhibitors in sickle cell disease: Abnormal levels and correlations with pulmonary hypertension, desaturation, haemolysis, organ dysfunction and death. Br J Haematol 2009; 145: 506-513.
60. Banerjee T, Kuypers FA. Reactive oxygen species and phosphatidylserine externalization in murine sickle red cells. Br J Haematol 2004; 124: 391-402.
61. Sugihara T, Rawicz W, Evans EA, et al. Lipid hydroperoxides permit deformation-dependent leak of monovalent cation from erythrocytes. Blood 1991; 77: 2757-2763.
62. Cesquini M, Torsoni MA, Stoppa GR, et al. t-BOOH-induced oxidative damage in sickle red blood cells and the role of flavonoids. Biomed Pharmacother 2003; 57: 124-129.
63. Suzuki J, Umeda M, Sims PJ, et al. Calcium-dependent phospholipid scrambling by TMEM16F. Nature 2010; 468: 834-838.
64. Neidlinger NA, Larkin SK, Bhagat A, et al. Hydrolysis of phosphatidylserine-exposing red blood cells by secretory phospholipase A2 generates lysophosphatidic acid and results in vascular dysfunction. J Biol Chem 2006; 281: 775-781.
65. Fadok VA, Bratton DL, Rose DM, et al. A receptor for phosphatidylserine- specific clearance of apoptotic cells. Nature 2000; 405: 85-90.
66. Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: Flow-cytometric measurement and clinical associations. Blood 1996; 88: 1873-1880.
67. Ataga KI, Orringer EP. Hypercoagulability in sickle cell disease: a curious paradox. Am J Med 2003; 115: 721-728.
68. van Beers EJ, Schaap MC, Berckmans RJ, et al. Circulating erythrocyte-derived microparticles are associated with coagulation activation in sickle cell disease. Haematologica 2009; 94: 1513-1519.
69. Lee SP, Ataga KI, Orringer EP, et al. Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 1626-1631.
70. Iuliano L, Colavita AR, Leo R, et al. Oxygen free radicals and platelet activation. Free Radic Biol Med 1997; 22: 999-1006.
71. Hammerschmidt DE. Tissue factor expression in sickle cell anemia. J Lab Clin Med 2001; 137: 440.
72. Schafer A, Alp NJ, Cai S, et al. Reduced vascular NO bioavailability in diabetes increases platelet activation in vivo. Arterioscler Thromb Vasc Biol 2004; 24: 1720-1726.
73. Jain SK, Shohet SB. A novel phospholipid in irreversibly sickled cells: evidence for in vivo peroxidative membrane damage in sickle cell disease. Blood 1984; 63: 362-367.
74. Setty BN, Kulkarni S, Stuart MJ. Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. Blood 2002; 99: 1564-1571.
75. Landesman SH, Rao SP, Ahonkhai VI. Infections in children with sickle cell anemia. Special reference to pneumococcal and salmonella infections. Am J Pediatr Hematol Oncol 1982; 4: 407-418.
76. Pearson HA. Sickle cell anemia and severe infections due to encapsulated bacteria. J Infect Dis 1977; 136 Suppl: 25-30.
77. Humbert JR, Winsor EL, Githens JM, et al. Neutrophil dysfunctions in sickle cell disease. Biomed Pharmacother 1990; 44: 153-158.
78. Amer J, Fibach E. Chronic oxidative stress reduces the respiratory burst response of neutrophils from beta-thalassaemia patients. Br J Haematol 2005; 129: 435-441.
79. Adelekan DA, Thurnham DI, Adekile AD. Reduced antioxidant capacity in paediatric patients with homozygous sickle cell disease. Eur J Clin Nutr 1989; 43: 609-614.
80. Dotan Y, Lichtenberg D, Pinchuk I. Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Prog Lipid Res 2004; 43: 200-227.
81. Roberts LJ, Morrow JD. Measurement of F(2)-isoprostanes as an index of oxidative stress in vivo. Free Radic Biol Med 2000; 28: 505-513.
82. Milne GL, Musiek ES, Morrow JD. F2-isoprostanes as markers of oxidative stress in vivo: An overview. Biomarkers 2005; 10 Suppl 1: 10-23.
83. Reid M, Badaloo A, Forrester T, et al. In vivo rates of erythrocyte glutathione synthesis in adults with sickle cell disease. Am J Physiol Endocrinol Metab 2006; 291: 73-79.
84. Jones DP. Redox potential of GSH/GSSG couple: assay and biological significance. Methods Enzymol 2002; 348: 93-112.
85. Ashfaq S, Abramson JL, Jones DP et al. The relationship between plasma levels of oxidized and reduced thiols and early atherosclerosis in healthy adults. J Am Coll Cardiol 2006; 47: 1005-1011.
86. Newsholme P, Lima MM, Procopio J et al. Glutamine and glutamate as vital metabolites. Braz J Med Biol Res 2003; 36: 153-163.
87. Kauf TL, Coates TD, Huazhi L, et al. The cost of health care for children and adults with sickle cell disease. Am J Hematol 2009; 84: 323-327.
88. Charache S, Dover GJ, Moyer MA, et al. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 1987; 69: 109-116.
89. Dasgupta T, Fabry ME, Kaul DK. Antisickling property of fetal hemoglobin enhances nitric oxide bioavailability and ameliorates organ oxidative stress in transgenic-knockout sickle mice. Am J Physiol Regul Integr Comp Physiol 2010; 298: 394-402.
90. Cho CS, Kato GJ, Yang SH et al. Hydroxyurea-induced expression of glutathione peroxidase 1 in red blood cells of individuals with sickle cell anemia. Antioxid Redox Signal 2010; 13: 1-11.
91. Dasgupta T, Hebbel RP, Kaul DK. Protective effect of arginine on oxidative stress in transgenic sickle mouse models. Free Radic Biol Med 2006; 41: 1771-1780.
92. Kaul DK, Zhang X, Dasgupta T, et al. Arginine therapy of transgenic-knockout sickle mice improves microvascular function by reducing non-nitric oxide vasodilators, hemolysis, and oxidative stress. Am J Physiol Heart Circ Physiol 2008; 295: 39-47.
93. Morris CR, Vichinsky EP, van WJ et al. Hydroxyurea and arginine therapy: impact on nitric oxide production in sickle cell disease. J Pediatr Hematol Oncol 2003; 25: 629-634.
94. Little JA, Hauser KP, Martyr SE et al. Hematologic, biochemical, and cardiopulmonary effects of L-arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapy. Eur J Haematol 2009; 82: 315-321.
95. Sullivan KJ, Kissoon N, Sandler E et al. Effect of Oral Arginine Supplementation on Exhaled Nitric Oxide Concentration in Sickle Cell Anemia and Acute Chest Syndrome. J Pediatr Hematol Oncol 2010; 32: 249-258.
96. Bendova P, Mackova E, Haskova P et al. Comparison of clinically used and experimental iron chelators for protection against oxidative stress-induced cellular injury. Chem Res Toxicol 2010; 23: 1105-1114.
97. Nur E, de Waart RD, Verwijs M et al. Increased Efflux of Oxidized Glutathione from Sickle Erythrocyte Causes Glutathione Depletion in Sickle Cell Disease. Abstract presented at ASH annual meeting. Blood 2009; 114: 11.
98. Amer J, Ghoti H, Rachmilewitz E, et al. Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol 2006; 132: 108-113.
99. Pace BS, Shartava A, Pack-Mabien A, et al. Effects of N-acetylcysteine ondense cell formation in sickle cell disease. Am J Hematol 2003; 73: 26-32.
100. Nur E, Brandjes DP, Teerlink T et al. N-acetylcysteine reduces oxidative stress in sickle cell patients. submitted for publication.
101. Amer J, Atlas D, Fibach E. N-acetylcysteine amide (AD4) attenuates oxidative stress in beta-thalassemia blood cells. Biochim Biophys Acta 2008; 1780: 249-255.
102. Chiu D, Vichinsky E, Ho SL, et al. Vitamin C deficiency in patients with sickle cell anemia. Am J Pediatr Hematol Oncol 1990; 12: 262-267.
103. Natta CL, Chen LC, Chow CK. Selenium and glutathione peroxidase levels in sickle cell anemia. Acta Haematol 1990; 83: 130-132.
104. Bao B, Prasad AS, Beck FW et al. Zinc supplementation decreases oxidative stress, incidence of infection, and generation of inflammatory cytokines in sickle cell disease patients. Transl Res 2008; 152: 67-80.
105. Muskiet FA, Muskiet FD, Meiborg G, et al. Supplementation of patients with homozygous sickle cell disease with zinc, alpha-tocopherol, vitamin C, soybean oil, and fish oil. Am J Clin Nutr 1991; 54: 736-744.
106. Osato JA, Santiago LA, Remo GM, et al. Antimicrobial and antioxidant activities of unripe papaya. Life Sci 1993; 53: 1383-1389.
107. Amer J, Goldfarb A, Rachmilewitz EA, et al. Fermented papaya preparation as redox regulator in blood cells of beta-thalassemic mice and patients. Phytother Res 2008; 22: 820-828.
108. Xia YF, Ye BQ, Li YD et al. Andrographolide attenuates inflammation by inhibition of NF-kappa B activation through covalent modification of reduced cysteine 62 of p50. J Immunol 2004; 173: 4207-4217.
109. Feeley BT, Park AK, Hoyt EG, et al. Sulfasalazine inhibits reperfusion injury and prolongs allograft survival in rat cardiac transplants. J Heart Lung Transplant 1999; 18: 1088-1095.
110. Kaul DK, Liu XD, Choong S, et al. Anti-inflammatory therapy ameliorates leukocyte adhesion and microvascular flow abnormalities in transgenic sickle mice. Am J Physiol Heart Circ Physiol 2004; 287: 293-301.
111. Solovey AA, Solovey AN, Harkness J, et al. Modulation of endothelial cell activation in sickle cell disease: A pilot study. Blood 2001; 97: 1937-1941.
112. Asami A, Orii M, Shirasugi N, et al. The effect of allopurinol on interstitial purine metabolism and tissue damage in skeletal muscle I-R injury. J Cardiovasc Surg (Torino) 1996; 37: 209-216.
113. Solovey A, Kollander R, Shet A et al. Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood 2004; 104: 840-846.